Loading…
← CockpitCompetitor Analysis › SYRE Spyre Therapeutics, IncOpen in the cockpit ↗

Spyre Therapeutics, IncSYRECompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Clinical-stage biotech developing long-acting antibody drugs for inflammatory bowel disease.

Momentum leader 84
Mkt cap
$9.64B
US dollars, full cap
Free float
90%
of shares outstanding
$/day
$95.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 20.0%
Hurdle
n/a
no reverse DCF
Next earnings
106 days
4 Mar 2027
Close · USD$101.46
1D+8.2%
1W-5.0%
1M+11.0%
3M-5.9%
6M+41.1%
YTD+209.7%
1Y+316.5%
ATR %5.6%
Beta1.68
52w lowhigh8.3% off high

What Spyre Therapeutics does

Clinical-stage biotech developing long-acting antibody drugs for inflammatory bowel disease.

Products and services

  • IBD antibody pipeline (pre-commercial)

Where it sits in the supply chain

  • Pharmaceuticals
  • Biotech
  • Immunology - inflammatory bowel disease

What could go right

  • Potential for less-frequent dosing than existing IBD biologics

What could go wrong

  • Pre-revenue clinical-trial risk
  • Crowded, well-capitalized IBD competitive field

Moat: none (IP / patents). Pre-commercial with no approved products yet; differentiation rests on longer-acting antibody engineering.

Headquarters: Waltham, Massachusetts, United States · Founded: 2022 · Employees: 102

Named competitors

Spyre Therapeutics at a glance

Size Spyre Therapeutics (SYRE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $9.64B, the 793rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $101.46 on 18 Nov 2026.

Performance Over six months the shares gained 41.1%, against +9.6% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.

Short interest Short interest is 12.2% of the free float (30 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026SYRE 137Peer median 112
Six months, rebased to 100: Spyre Therapeutics against the median of its 20 peers (local-currency closes).

Spyre Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$886,000$2.33M
Revenue growth——-100%-62%—
Gross profit$0$0$0-$78,000$365,000
EBITDA-$320M-$220M-$209M-$117M-$82.8M
Net income-$253M-$127M-$150M-$94.9M-$83.8M
Free cash flown/an/a-$158M-$99.9M-$80.2M
Capital expenditure$0$0$0$0$38,000
Total debt$0$0$0$84.6M$4.64M

Quarterly statements and history in the cockpit →

Spyre Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%+60%0%+20%3759TGTXMDGLHLUN-APRAX4151RGENPTGX2607RYTMMANKIND600436GLENMARKALK-BALKSREC21961177AMRXGRFSYRE6-month return →1-month return →
Up and to the right = strong over both horizons. Spyre Therapeutics is the large dot.

Spyre Therapeutics competitors and peer comparison

Head to head with its named competitors (SYRE vs ABBV vs JNJ vs PFE)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Spyre Therapeutics SYRE$9.64B+41%n/an/an/an/a
AbbVie ABBV$506B+35%+11%36%8.7×-0.1%
Johnson & Johnson JNJ$656B+20%+8%26%6.9×3.7%
Pfizer PFE$160B+9%+1%26%3.3×-4.3%

How Spyre Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Spyre Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureSYREPeer medianRank in peer set
1-month return+11.0%+5.6%8th highest of 21
6-month return+41.1%+9.6%6th highest of 21
Distance from 52-week high-8.3%-11.2%9th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Spyre Therapeutics SYREUnited States$9.64B+41%n/an/an/an/an/a
Pharmaron Beijing 3759.HKHong Kong$9.65B+48%+24%14%4.4×n/an/a
TG Therapeutics TGTXUnited States$9.99B+66%+69%21%11.4×43.0%+426.7%
Madrigal Pharmaceuticals MDGLUnited States$9.25B-22%+93%-11%6.0×n/an/a
H. Lundbeck A/S HLUN-A.CODenmark$9.16B+69%+9%26%2.6×-6.6%+6.6%
Praxis Precision Medicines PRAXUnited States$8.53B-9%-100%n/an/an/an/a
Kyowa Kirin 4151.TJapan$8.43B+9%+10%24%2.1×-4.7%+9.3%
Repligen RGENUnited States$11.0B+55%+14%9%13.5×56.9%+15.0%
Protagonist Therapeutics PTGXUnited States$8.30B+26%+164%59%13.6×17.5%+10.0%
Shanghai Pharmaceuticals 2607.HKHong Kong$8.25B-7%+9%3%0.3×-9.7%+7.4%
Rhythm Pharmaceuticals RYTMUnited States$8.25B+31%+61%-67%29.0×n/an/a
Mankind Pharma MANKIND.NSIndia$11.6B+5%+13%21%7.2×28.6%+18.1%
Zhangzhou Pientzehuang Pharmaceutical 600436.SSChina$11.6B-4%-19%19%9.7×24.9%+6.8%
Glenmark Pharmaceuticals GLENMARK.NSIndia$7.98B+10%0%17%4.7×27.3%+9.4%
ALK-abello A/S ALK-B.CODenmark$7.94B-8%+16%26%7.4×7.3%+12.6%
Alkermes Public ALKSUnited States$7.87B+27%+15%5%5.0×32.5%+7.3%
Recordati REC.MIItaly$12.0B+3%+8%30%4.5×1.1%+12.6%
Shanghai Fosun Pharmaceutical (Group) 2196.HKHong Kong$7.74B-15%+10%6%2.2×19.9%+5.8%
Sbp 1177.HKHong Kong$12.2B+5%+15%30%2.6×-5.7%+5.4%
Amneal Pharmaceuticals AMRXUnited States$7.62B+79%+9%16%3.4×17.2%+8.7%
Grifols GRF.MCSpain$7.48B+19%+1%16%2.4×7.1%+7.1%

Questions

Who are Spyre Therapeutics's main competitors?
Named competitors: AbbVie (ABBV), Johnson & Johnson (JNJ), Pfizer (PFE). The cockpit's measured peer set (industry) also includes Pharmaron Beijing (3759.HK), TG Therapeutics (TGTX), Madrigal Pharmaceuticals (MDGL), H. Lundbeck A/S (HLUN-A.CO), Praxis Precision Medicines (PRAX), Kyowa Kirin (4151.T).
How has Spyre Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +41.1% against +9.6% for the median peer; over one year +316.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.